A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome

Roger Kurlan; Giovanna Crespi; Barbara Coffey; Kirsten Mueller-Vahl; Stephen Koval; Glen Wunderlich; Kirsten Mueller-Vahl; Andrea Ludolph; Johathan Liss; Barbara Coffey; Donald Lewis; Michael Bengtson; Jose Zaglul; Willis Holloway; Judith Owens; Cathy Budman; Joseph Jankovic; Moira Rynn; Daniel Geller; Katie Kompoliti; Mark LeDoux

doi:10.1002/mds.24919

A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome

Roger Kurlan, Giovanna Crespi, Barbara Coffey, Kirsten Mueller-Vahl, Stephen Koval, Glen Wunderlich, Kirsten Mueller-Vahl, Andrea Ludolph, Johathan Liss, Barbara Coffey, Donald Lewis, Michael Bengtson, Jose Zaglul, Willis Holloway, Judith Owens, Cathy Budman, Joseph Jankovic, Moira Rynn, Daniel Geller, Katie KompolitiMark LeDoux

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole -7.16) and placebo -7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.

Original language	English (US)
Pages (from-to)	775-778
Number of pages	4
Journal	Movement Disorders
Volume	27
Issue number	6
DOIs	https://doi.org/10.1002/mds.24919
State	Published - May 2012
Externally published	Yes

Keywords

Dopamine agonist
Pramipexole
Tics
Tourette's syndrome
Treatment, clinical trial

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.24919

Cite this

Kurlan, R., Crespi, G., Coffey, B., Mueller-Vahl, K., Koval, S., Wunderlich, G., Mueller-Vahl, K., Ludolph, A., Liss, J., Coffey, B., Lewis, D., Bengtson, M., Zaglul, J., Holloway, W., Owens, J., Budman, C., Jankovic, J., Rynn, M., Geller, D., ... LeDoux, M. (2012). A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Movement Disorders, 27(6), 775-778. https://doi.org/10.1002/mds.24919

A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. / Kurlan, Roger; Crespi, Giovanna; Coffey, Barbara; Mueller-Vahl, Kirsten; Koval, Stephen; Wunderlich, Glen; Mueller-Vahl, Kirsten; Ludolph, Andrea; Liss, Johathan; Coffey, Barbara; Lewis, Donald; Bengtson, Michael; Zaglul, Jose; Holloway, Willis; Owens, Judith; Budman, Cathy; Jankovic, Joseph; Rynn, Moira; Geller, Daniel; Kompoliti, Katie; LeDoux, Mark.

In: Movement Disorders, Vol. 27, No. 6, 05.2012, p. 775-778.

Research output: Contribution to journal › Article › peer-review

Kurlan, R, Crespi, G, Coffey, B, Mueller-Vahl, K, Koval, S, Wunderlich, G, Mueller-Vahl, K, Ludolph, A, Liss, J, Coffey, B, Lewis, D, Bengtson, M, Zaglul, J, Holloway, W, Owens, J, Budman, C, Jankovic, J, Rynn, M, Geller, D, Kompoliti, K & LeDoux, M 2012, 'A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome', Movement Disorders, vol. 27, no. 6, pp. 775-778. https://doi.org/10.1002/mds.24919

Kurlan, Roger ; Crespi, Giovanna ; Coffey, Barbara ; Mueller-Vahl, Kirsten ; Koval, Stephen ; Wunderlich, Glen ; Mueller-Vahl, Kirsten ; Ludolph, Andrea ; Liss, Johathan ; Coffey, Barbara ; Lewis, Donald ; Bengtson, Michael ; Zaglul, Jose ; Holloway, Willis ; Owens, Judith ; Budman, Cathy ; Jankovic, Joseph ; Rynn, Moira ; Geller, Daniel ; Kompoliti, Katie ; LeDoux, Mark. / A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. In: Movement Disorders. 2012 ; Vol. 27, No. 6. pp. 775-778.

@article{4d256b9007794f28873360814a0c0846,

title = "A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome",

abstract = "Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole -7.16) and placebo -7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.",

keywords = "Dopamine agonist, Pramipexole, Tics, Tourette's syndrome, Treatment, clinical trial",

author = "Roger Kurlan and Giovanna Crespi and Barbara Coffey and Kirsten Mueller-Vahl and Stephen Koval and Glen Wunderlich and Kirsten Mueller-Vahl and Andrea Ludolph and Johathan Liss and Barbara Coffey and Donald Lewis and Michael Bengtson and Jose Zaglul and Willis Holloway and Judith Owens and Cathy Budman and Joseph Jankovic and Moira Rynn and Daniel Geller and Katie Kompoliti and Mark LeDoux",

year = "2012",

month = may,

doi = "10.1002/mds.24919",

language = "English (US)",

volume = "27",

pages = "775--778",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome

AU - Kurlan, Roger

AU - Crespi, Giovanna

AU - Coffey, Barbara

AU - Mueller-Vahl, Kirsten

AU - Koval, Stephen

AU - Wunderlich, Glen

AU - Mueller-Vahl, Kirsten

AU - Ludolph, Andrea

AU - Liss, Johathan

AU - Coffey, Barbara

AU - Lewis, Donald

AU - Bengtson, Michael

AU - Zaglul, Jose

AU - Holloway, Willis

AU - Owens, Judith

AU - Budman, Cathy

AU - Jankovic, Joseph

AU - Rynn, Moira

AU - Geller, Daniel

AU - Kompoliti, Katie

AU - LeDoux, Mark

PY - 2012/5

Y1 - 2012/5

N2 - Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole -7.16) and placebo -7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.

AB - Background: Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome. Methods: There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome. Results: There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole -7.16) and placebo -7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. Conclusions: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.

KW - Dopamine agonist

KW - Pramipexole

KW - Tics

KW - Tourette's syndrome

KW - Treatment, clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84861682566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861682566&partnerID=8YFLogxK

U2 - 10.1002/mds.24919

DO - 10.1002/mds.24919

M3 - Article

C2 - 22407510

AN - SCOPUS:84861682566

VL - 27

SP - 775

EP - 778

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -

A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this